Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy
- PMID: 1552912
- DOI: 10.1056/NEJM199204233261703
Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy
Abstract
Background: Familial hypertrophic cardiomyopathy is characterized by a variable degree of myocardial hypertrophy and a wide range of symptoms. Different mutations in the beta cardiac myosin heavy-chain gene have been identified in three affected families. However, neither the proportion of cases attributable to myosin mutations nor the effects of different mutations on clinical outcome are known.
Methods: Using a ribonuclease protection assay, we screened the beta cardiac myosin heavy-chain genes of probands from 25 unrelated families with familial hypertrophic cardiomyopathy; this assay is a sensitive method for detecting the presence and location of mutations. We further defined the mutations by analyzing their nucleotide sequences. The clinical features of the disease were compared in families with various myosin mutations.
Results: Seven mutations in the beta cardiac myosin heavy-chain gene were identified in 12 of the 25 families. All were missense mutations (i.e., causing the substitution of a single amino acid) clustered in the head and head-rod junction regions of the molecule. Six mutations resulted in a change in the charge of the amino acid. Patients with mutations that changed the charge of the altered amino acid (such as that from arginine to glutamine at nucleotide 403 or from arginine to cysteine at nucleotide 453) had a significantly shorter life expectancy (mean age at death, 33 years), whereas patients with the one mutation that did not produce a change in charge (Val606Met) had nearly normal survival. However, patients with different mutations did not differ appreciably in their clinical manifestations of familial hypertrophic cardiomyopathy.
Conclusions: Different missense mutations in the beta cardiac myosin heavy-chain gene can be identified in approximately 50 percent of families with hypertrophic cardiomyopathy. In those families, a definite genetic diagnosis can be made in all members. Since the location of a mutation or its DNA-sequence alteration (or both) appears to influence survival, we suggest that the precise definition of the disease-causing mutation can provide important prognostic information about affected members.
Comment in
-
Genetic testing for hypertrophic cardiomyopathy.N Engl J Med. 1992 Oct 15;327(16):1175-6. doi: 10.1056/NEJM199210153271616. N Engl J Med. 1992. PMID: 1528221 No abstract available.
Similar articles
-
Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes.N Engl J Med. 1991 Dec 19;325(25):1753-60. doi: 10.1056/NEJM199112193252501. N Engl J Med. 1991. PMID: 1944483
-
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.N Engl J Med. 1998 Apr 30;338(18):1248-57. doi: 10.1056/NEJM199804303381802. N Engl J Med. 1998. PMID: 9562578
-
Beta-myosin heavy chain gene mutations and hypertrophic cardiomyopathy in Austrian children.J Mol Cell Cardiol. 2001 Jan;33(1):141-8. doi: 10.1006/jmcc.2000.1287. J Mol Cell Cardiol. 2001. PMID: 11133230
-
[Structural analysis of cardiac beta myosin heavy chain gene in familial hypertrophic cardiomyopathy].Nihon Rinsho. 1993 Jun;51(6):1448-52. Nihon Rinsho. 1993. PMID: 8320828 Review. Japanese.
-
[Cardiomyopathies from the aspect of molecular cardiology].Cas Lek Cesk. 1994 Jun 27;133(13):401-3. Cas Lek Cesk. 1994. PMID: 8062332 Review. Czech.
Cited by
-
Using genetic testing to guide therapeutic decisions in cardiomyopathy.Curr Treat Options Cardiovasc Med. 2013 Aug;15(4):387-96. doi: 10.1007/s11936-013-0252-7. Curr Treat Options Cardiovasc Med. 2013. PMID: 23794152 Free PMC article.
-
Is QT dispersion associated with sudden cardiac death in patients with hypertrophic cardiomyopathy?Ann Noninvasive Electrocardiol. 2001 Jul;6(3):209-15. doi: 10.1111/j.1542-474x.2001.tb00110.x. Ann Noninvasive Electrocardiol. 2001. PMID: 11466139 Free PMC article.
-
Sudden death in hypertrophic cardiomyopathy.J Cardiovasc Transl Res. 2009 Dec;2(4):368-80. doi: 10.1007/s12265-009-9147-0. Epub 2009 Nov 13. J Cardiovasc Transl Res. 2009. PMID: 20559995 Review.
-
The genomics of cardiovascular disorders: therapeutic implications.Drugs. 2000 May;59(5):1025-42. doi: 10.2165/00003495-200059050-00001. Drugs. 2000. PMID: 10852637 Review.
-
Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy.Br Heart J. 1994 Dec;72(6 Suppl):S13-8. doi: 10.1136/hrt.72.6_suppl.s13. Br Heart J. 1994. PMID: 7873317 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases